Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1

US8673899B2 · kind B2 · utility

Assignees

• Vitae Pharmaceuticals, LLC · US
• Boehringer Ingelheim International GmbH · DE

Inventors

• David A. Claremon · Audubon, US
• Linghang Zhuang · Doylestown, US
• Katerina Leftheris · Skillman, US
• Colin M. Tice · Ambler, US
• Zhenrong Xu · Forest Park, US
• Yuanjie Ye · Ambler, US
• Suresh B. Singh · Kendall Park, US
• Salvacion Cacatian · Conshohocken, US
• Wei Zhao · North Potomac, US

Key dates

• Filing date: Jan 11, 2012
• Grant date: Mar 18, 2014
• Expiry date: Jan 11, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.